2006 - april -
Northwest Biotherapeutics to Present at BIO 2006 Business Forum
Highlights Include New Funding and Monoclonal Antibody Product Candidate
BOTHELL, Wash., April 6 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB) today announced that its President and Chief Operating Officer, Dr. Alton Boynton, will give a corporate presentation at the Biotechnology Industry Organization's BIO
2006 Annual International Convention being held April 9th-12th, in Chicago, Illinois. Dr. Boynton is scheduled to present as part of the BIO Business Forum on Monday, April 10th, 2006 at 2:15 pm in Room B, McCormick Place
South, Exhibit Hall A.
Dr. Boynton will provide an update on Northwest's product candidates, including therapeutic cancer vaccines DCVax(R)-Brain for glioblastoma multiforme and DCVax(R)-Prostate for hormone-independent prostate cancer, and monoclonal antibodies against CXCR4. CXCR4 has been shown to play a
major role in the progression and spread of over 75% of all cancers.
Northwest Biotherapeutics recently announced a $5.5 million private placement, and is in late stage clinical development with both DCVax(R)-Brain and DCVax(R)-Prostate.
About DCVax(R)-Brain and DCVax(R)-Prostate
DCVax(R)-Brain and DCVax(R)-Prostate are personalized vaccines designed to stimulate a patient's own immune system to fight cancer. They are therapeutic vaccines to treat existing disease. DCVax(R)-Brain and DCVax(R)-Prostate are made up of the patient's own dendritic cells that have been "educated" to recognize and kill cancer cells bearing the
biomarkers of the patient's tumor. These vaccines are administered through a simple injection under the skin, similar to an insulin or flu shot.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines,
and therapeutic antibodies. The Company's three lead product candidates are: DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a
Phase III clinical trial recently cleared by the FDA ; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial recently cleared by the FDA; and monoclonal antibodies to CXCR4, which are
in late preclinical development for the treatment of cancer.
For further information, please visit the company web site at nwbio.com.
prnewswire.com |
